Phytotherapy-Induced Hepatocytotoxicity: A Case Report
Abstract
:1. Introduction
2. Case Report
3. Methods
3.1. Pathology
3.2. Cytokines and Chemokines
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
ALT | Alanine aminotransferase (glutamic-pyruvic transaminase, GPT) |
ALP | Alkaline phosphatase |
AST | Aspartate amino-transferase (glutamic-oxalo-acetic transaminase, GOT) |
AUC | Area under the curve |
BCAA | Branched chain amino acids |
CB | Conjugated (direct) bilirubin |
CCL2 (MCP-1) | Metalloproteinase 1 |
CCL5 (RANTES) | Regulated upon activation, normal T cell expressed and presumably secreted |
CCR5 | Ligand (MIP)- macrophage inflammatory protein -1 |
CIOMS | Council for International Organizations of Medical Sciences |
DILI | Drug-induced liver injury |
ECM | Extracellular matrix |
ELISA | Enzyme-linked immunosorbent assay |
GGT | γ-glutamyl-transferase (γ-glutamyl-transpeptidase, GGTP) |
HILI | Herbal-induced liver injury |
IFNβ | Interferon beta |
IFN γ | Interferon gamma |
IL | Interleukin: IL1-α IL1β, IL2, IL4, IL6, IL8, IL 15 |
INR | International Normalized Ratio |
LTA | Lymphocyte toxicity assay |
MMP | Matrix metalloprotease |
MTT | 3-(4,5-dimethyl-thiazol-2-yl)-2,5-dio-phenyl tetrazolium bromide |
NFκB | Nuclear factor κ-B (transcription factor) |
NKT | Natural killer cells |
PDGF | Platelet-derived growth factor |
RUCAM | Roussel Uclaf Causality Assessment Method |
SDH | Succinate dehydrogenase |
TGF | β Transforming growth factor beta |
TLR | Tall like receptor |
TNFα | Tumor necrosis factor alpha |
TRAIL | Tumor necrosis factor related apoptosis-inducing ligand-(APO-2L) |
ULN | Upper limit of the normal reference range |
VEGF | Vascular endothelial growth factor |
Acute inflammation | elevated CCL5 (RANTES), IL1–α, IL1–β, IL6, IL8, IL-15, TNF–α |
References
- Zimmerman, H.J. The spectrum of hepatotoxicity. Perspect. Biol. Med. 1968, 12, 135–161. [Google Scholar] [CrossRef]
- Navarro, V.J.; Senior, J.R. Drug-related hepatotoxicity. N. Engl. J. Med. 2006, 354, 731–739. [Google Scholar] [CrossRef] [PubMed]
- Zimmerman, H.J. Hepatotoxicity: The Adverse Effects of Drug and Other Chemicals on the Hepatic; Lippinocott, Williams and Wilkins: Philadelphia, PA, USA, 1999. [Google Scholar]
- Lee, W.M.; Senior, J.R. Recognizing drug-induced liver injury: Current problems, possible solutions. Toxicol. Pathol. 2005, 33, 155–164. [Google Scholar] [CrossRef]
- Malnick, S.; Maor, Y.; Melzer, E.; Ziv-Sokolowskaia, N.N.; Neuman, M.G. Severe hepatocytotoxicity linked to denosumab. Eur. Rev. Med. Pharmacol. Sci. 2017, 21, 78–85. [Google Scholar]
- Neuman, M.G.; Ishay, J.S.; Waron, M.; Zimmerman, H.J.; Eshchar, J. Hepatotoxicity induced by the Oriental hornet (Vespa orientalis) venom sac extract. Pharmacol. Toxicol. 1991, 69 (Suppl. S1), 1–36. [Google Scholar] [CrossRef] [PubMed]
- Pessayre, D.; Feldman, G.; Haouzi, D.; Fau, A.; Moreau, A.; Neuman, M. Hepatocyte Apoptosis triggered bynatural substances (cytokines, other endogenous molecules and foreign toxins). In Handbook of Experimental Pharmacology: Apoptosis Modulation by Drugs; Cameron, R.G., Farber, G., Eds.; Springer: Berlin/Heidelberg, Germany, 1999; pp. 69–109. [Google Scholar] [CrossRef]
- Neuman, M.G.; Malkiewicz, I.M.; Shear, N.H. A Novel Lymphocyte Toxicity Assay to Assess Drug Hypersensitivity Syndromes. Clin. Biochem. 2000, 33, 517–524. [Google Scholar] [CrossRef] [PubMed]
- Neuman, M.G.; Cohen, L.B.; Steenkamp, V. Pyrrolizidine alkaloids enhance alcohol-induced hepatocytotoxicity in vitro in normal human hepatocytes. Eur. Rev. Med. Pharmacol. Sci. 2017, 21, 53–68. [Google Scholar] [PubMed]
- Aithal, G.P.; Rawlins, M.D.; Day, C.P. Clinical diagnostic scale: A useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J. Hepatol. 2000, 33, 949–952. [Google Scholar] [CrossRef] [PubMed]
- Andrade, R.J.; Robles, M.; Lucena, M.I. Rechallenge in drug-induced liver injury: The attractive hazard. Expert Opin. Drug Saf. 2009, 8, 709–714. [Google Scholar] [CrossRef]
- Daly, A.K. Drug-induced liver injury: Past, present and future. Pharmacogenomics 2010, 11, 607–611. [Google Scholar] [CrossRef]
- Hollenberg, P.F. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab. Rev. 2002, 34, 17–35. [Google Scholar] [CrossRef] [PubMed]
- Hurrell, R.F.; Reddy, M.; Cook, J.D. Inhibition of non-haem iron absorption in man by polyphenolic-containing beverages. Br. J. Nutr. 1999, 81, 289–295. [Google Scholar] [CrossRef] [PubMed]
- Assis, D.N.; Navarro, V.J. Human drug hepatotoxicity: A contemporary clinical perspective. Expert Opin. Drug Metab. Toxicol. 2009, 5, 463–473. [Google Scholar] [CrossRef]
- Danan, G.; Benichou, C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J. Clin. Epidemiol. 1993, 46, 1323–1330. [Google Scholar] [CrossRef] [PubMed]
- Bénichou, C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J. Hepatol. 1990, 11, 272–276. [Google Scholar] [CrossRef] [PubMed]
- Fontana, R.J.; Seef, L.B.; Andrade, R.J.; Bjornsson, J.; Day, C.P.; Serrano, J.; Hoofnagle, J.H. Standardization of nomenclature and causality assessment in drug-induced liver injury: Summary of a clinical research workshop. Hepatology 2010, 52, 730–742. [Google Scholar] [CrossRef]
- Zimmerman, H.J.; Chomet, B.; Kulesh, M.H.; McWhorter, C.A. Hepatic hemosiderin deposits. Incidence in 558 biopsies from patients with and without intrinsic hepatic disease. Arch. Intern. Med. 1961, 107, 494–503. [Google Scholar] [CrossRef] [PubMed]
- Bonkovsky, H.L. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann. Intern. Med. 2006, 144, 68–71. [Google Scholar] [CrossRef] [PubMed]
- Javaid, A.; Bonkovsky, H.L. Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): A growing concern. J. Hepatol. 2006, 45, 334–336. [Google Scholar] [CrossRef] [PubMed]
- Jimenez-Saenz, M.; Martinez-Sanchez, M.D.C. Acute hepatitis associated with the use of green tea infusions. J. Hepatol. 2006, 44, 616–617. [Google Scholar] [CrossRef] [PubMed]
- Molinari, M.; Watt, K.D.; Kruszyna, T.; Nelson, R.; Walsh, M.; Huang, W.Y.; Nashan, B.; Peltekian, K. Acute liver failure induced by green tea extracts: Case report and review of the literature. Liver Transplant. 2006, 12, 1892–1895. [Google Scholar] [CrossRef] [PubMed]
- Stevens, T.; Qadri, A.; Zein, N.N. Two patients with acute liver injury associated with use of the herbal weight-loss supplement hydroxycut. Ann. Intern. Med. 2005, 142, 477–478. [Google Scholar] [CrossRef] [PubMed]
- Neuman, M.G. Apoptosis in diseases of the liver. Crit. Rev. Clin. Lab. Sci. 2001, 38, 109–166. [Google Scholar] [CrossRef] [PubMed]
- Neuman, M.G. Personalized medicine, preventing and treating adverse drug reactions. Biotechnol. Focus 2006, 4, 13–16. [Google Scholar]
- Bénichou, C.; Danan, G.; Flahault, A. Causality assessment of adverse reactions of drugs—II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge. J. Clin. Epidemiol. 1993, 46, 1331–1336. [Google Scholar] [CrossRef]
- Danan, G.; Teschke, R. Roussel Uclaf Causality Assessment Method for Drug-Induced Liver Injury: Present and Future. Front. Pharmacol. 2019, 10, 853. [Google Scholar] [CrossRef]
- Brew, K.; Dinakarpandian, D.; Nagase, H. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim. Biophys. Acta 2000, 1477, 267–283. [Google Scholar] [CrossRef] [PubMed]
- Danan, G.; Teschke, R. RUCAM in drug and herb induced liver injury: The update. Int. J. Mol. Sci. 2016, 17, 14. [Google Scholar] [CrossRef] [PubMed]
- Teschke, R.; Danan, G. Idiosyncratic DILI and RUCAM under one hat: The global view. Livers 2023, 3, 397–434. [Google Scholar] [CrossRef]
- Teschke, R.; Danan, G. Advances in idiosyncratic drug induced liver injury issues: New clinical and mechanistic analysis due to Roussel Uclaf Causality Assessment Method use. In Special Issue: Molecular Toxicology of Drug Induced Liver Injury, section of Molecular Toxicology. Int. J. Mol. Sci. 2023, 24, 10855. [Google Scholar] [CrossRef]
- Ortega-Alonso, A.; Stephens, C.; Lucena, M.I.; Andrade, R.J. Case characterization, clinical features and risk factors in drug-induced liver injury. Int. J. Mol. Sci. 2016, 17, 714. [Google Scholar] [CrossRef]
- Naranjo, C.A.; Busto, U.; Sellers, E.M.; Sandor, P.; Ruiz, I.; Roberts, E.A.; Janecek, E.; Domecq, C.; Greenblatt, D.J. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981, 30, 239–245. [Google Scholar] [CrossRef] [PubMed]
- Gallagher, R.M.; Kirkha, J.J.; Mason, J.R.; Bird, K.A.; Williamson, P.R.; Nunn, A.J.; Turner, M.A.; Smyth, R.L.; Pirmohamed, M. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS ONE 2011, 6, e28096. [Google Scholar] [CrossRef] [PubMed]
- Stedman, C. Herbal hepatotoxicity. Semin. Liver Dis. 2002, 22, 195–206. [Google Scholar] [CrossRef] [PubMed]
- Parvez, M.K.; Rishi, V. Herb-Drug Interactions and Hepatotoxicity. Curr. Drug Metab. 2019, 20, 275–282. [Google Scholar] [CrossRef] [PubMed]
Date | ALP | ALT | AST | GGT | Bilirubin Total/Direct |
---|---|---|---|---|---|
Normal range | 30–280 IU/L | 0–45 IU/L | 0–35 IU/L | 0–55 IU/L | 0.3–1.2 mg/dL 0.1–0.3 mg/dL |
27 February 2023 | 90 | 127 | 66 | 17 | 0.4/0.1 |
9 March 2023 | 87 | 202 | 119 | 20 | 0.4/0.1 |
27 April 2023 | 77 | 67 | 44 | 18 | 0.4/0.1 |
30 July 2023 | 91 | 43 | 35 | 16 | 0.4/0.1 |
1 September 2023 | 90 | 32 | 35 | 20 | 0.4/0.1 |
16 November 2023 | 91 | 41 | 35 | 21 | 0.4/012 |
Cytokine | Normal Values | Sera-09-1-2023 | Medium 24 h Exposure |
---|---|---|---|
IFN-β pg/mL | 20–40 | 44 | 22 |
IFN-γ pg/mL | 15–40 | 80 | 20 |
IL-1beta pg/mL | 20–50 | 90 | 35 |
IL-2 pg/mL | 15–30 | 30 | 36 |
IL-4 pg/mL | 15–30 | 20 | 18 |
IL-6 pg/mL | 30–60 | 52 | 54 |
IL-8 pg/mL | 20–60 | 120 | 42 |
IL 13 pg/mL | 24–40 | 80 | 44 |
IL-15 pg/mL | 15–30 | 60 | 38 |
MMP pg/mL | 20–40 | 60 | 52 |
NFκB pg/mL | 15–40 | 126 | 46 |
RANTES pg/mL | 15–50 | 46 | 50 |
TGF-β ng/mL | 20–40 | 40 | 32 |
TNF-α pg/mL | 25–50 | 650 | 66 |
TRAIL pg/mL | 15–40 | 620 | 40 |
VEGF pg/mL | 20–90 | 906 | 85 |
ccK18 (M-30) U/L | 68–132 | 130 | 80 |
ccK8 (M65) U/L | 62–200 | 300 | 80 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Malnick, S.; Abdullah, A.; Maor, Y.; Neuman, M.G. Phytotherapy-Induced Hepatocytotoxicity: A Case Report. Curr. Issues Mol. Biol. 2024, 46, 7548-7557. https://doi.org/10.3390/cimb46070448
Malnick S, Abdullah A, Maor Y, Neuman MG. Phytotherapy-Induced Hepatocytotoxicity: A Case Report. Current Issues in Molecular Biology. 2024; 46(7):7548-7557. https://doi.org/10.3390/cimb46070448
Chicago/Turabian StyleMalnick, Stephen, Ali Abdullah, Yaacov Maor, and Manuela G. Neuman. 2024. "Phytotherapy-Induced Hepatocytotoxicity: A Case Report" Current Issues in Molecular Biology 46, no. 7: 7548-7557. https://doi.org/10.3390/cimb46070448
APA StyleMalnick, S., Abdullah, A., Maor, Y., & Neuman, M. G. (2024). Phytotherapy-Induced Hepatocytotoxicity: A Case Report. Current Issues in Molecular Biology, 46(7), 7548-7557. https://doi.org/10.3390/cimb46070448